Evommune, Inc. - 8-K Filing
Evommune enters exclusive license agreement with Hinova Pharmaceuticals for VAV1 degraders and completes $30 million private placement. (Items: 1.01 Entry into a Material Definitive Agreement, 3.02 Unregistered Sales of Equity Securities, 7.01 Regulation FD Disclosure, 8.01 Other Events)
Tickers: $EVMN
Read the full article at SEC EDGAR
Part of the story INTRUSION INC - 8-K Filing (4 articles)